| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 6,493 | 6,691 | 6,973 | 7,260 | 7,622 | 8,164 | 7,869 | 7,805 | 7,050 | 6,319 | 6,845 | 6,727 | 7,014 | 7,339 | 7,198 | 7,850 | 7,326 | 8,472 | 8,150 | 8,159 | 8,180 | 7,640 | 9,019 | 9,124 | 8,575 | 9,822 | 9,780 | 10,247 | 9,500 | 10,646 | 10,894 | 11,274 | 11,099 | 11,990 | 12,297 | 12,407 | 12,419 | 13,057 | 13,618 | 13,903 |
| Expenses | 5,318 | 5,679 | 5,000 | 4,877 | 5,382 | 5,335 | 5,092 | 5,472 | 5,590 | 6,064 | 5,275 | 5,200 | 5,294 | 5,618 | 6,621 | 5,587 | 6,147 | 6,379 | 6,334 | 6,314 | 7,083 | 9,375 | 6,360 | 6,431 | 7,147 | 7,529 | 6,996 | 7,257 | 11,042 | 7,877 | 7,996 | 8,237 | 8,300 | 8,932 | 9,013 | 8,974 | 9,049 | 9,045 | 9,352 | 9,983 |
| EBITDA | 1,175 | 1,012 | 1,973 | 2,383 | 2,240 | 2,829 | 2,776 | 2,333 | 1,460 | 255 | 1,570 | 1,528 | 1,720 | 1,721 | 577 | 2,263 | 1,179 | 2,094 | 1,816 | 1,845 | 1,098 | -1,736 | 2,659 | 2,693 | 1,427 | 2,293 | 2,784 | 2,990 | -1,542 | 2,769 | 2,899 | 3,037 | 2,799 | 3,058 | 3,284 | 3,433 | 3,370 | 4,012 | 4,266 | 3,920 |
| Operating Profit % | 13 % | 13 % | 27 % | 31 % | 27 % | 33 % | 34 % | 29 % | 18 % | 2 % | 20 % | 21 % | 21 % | 21 % | 3 % | 27 % | 13 % | 23 % | 20 % | 21 % | 12 % | -25 % | 25 % | 27 % | 16 % | 22 % | 27 % | 26 % | -18 % | 26 % | 26 % | 26 % | 23 % | 24 % | 25 % | 26 % | 23 % | 28 % | 29 % | 26 % |
| Depreciation | 462 | 240 | 258 | 251 | 288 | 316 | 304 | 307 | 338 | 347 | 359 | 339 | 455 | 402 | 427 | 471 | 454 | 457 | 473 | 547 | 575 | 496 | 499 | 532 | 554 | 503 | 530 | 554 | 557 | 588 | 610 | 660 | 672 | 651 | 633 | 622 | 650 | 655 | 626 | 631 |
| Interest | 135 | 135 | 158 | 128 | 103 | 135 | 54 | 167 | 45 | 109 | 157 | 95 | 155 | 131 | 130 | 145 | 150 | 104 | 84 | 63 | 52 | 52 | 33 | 26 | 30 | 35 | 36 | 19 | 37 | 14 | 19 | 46 | 93 | 81 | 49 | 35 | 74 | 62 | 69 | 52 |
| Profit Before Tax | 591 | 872 | 1,572 | 2,040 | 2,087 | 2,628 | 2,930 | 2,102 | 1,389 | -159 | 1,114 | 1,148 | 1,376 | 1,274 | 112 | 1,730 | 694 | 1,647 | 1,433 | 1,351 | 577 | -2,184 | 2,206 | 2,163 | 903 | 1,804 | 2,287 | 2,466 | -2,076 | 2,285 | 2,412 | 2,472 | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 |
| Tax | -596 | 115 | 272 | 100 | 424 | 360 | 458 | 380 | 3 | 164 | 113 | 792 | -187 | 88 | 272 | 269 | -26 | 151 | 270 | 332 | 85 | 242 | 263 | 250 | 61 | 400 | 200 | 340 | 152 | 191 | 157 | 291 | 257 | 476 | 406 | 440 | 157 | 563 | 561 | 563 |
| Net Profit | 1,186 | 757 | 1,299 | 1,940 | 1,663 | 2,268 | 2,471 | 1,722 | 1,386 | -323 | 1,002 | 356 | 1,563 | 1,186 | -160 | 1,461 | 721 | 1,497 | 1,163 | 1,019 | 493 | -2,426 | 1,943 | 1,913 | 842 | 1,404 | 2,086 | 2,126 | -2,227 | 2,093 | 2,256 | 2,181 | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 |
| EPS in ₹ | 3.70 | 2.30 | 4.30 | 6.40 | 5.90 | 8.50 | 9.30 | 6.10 | 5.20 | -1.77 | 3.80 | 1.34 | 5.60 | 4.41 | -1.12 | 5.18 | 2.65 | 5.78 | 4.43 | 3.81 | 1.67 | -6.90 | 7.56 | 7.72 | 3.70 | 6.00 | 8.50 | 8.60 | -9.50 | 8.60 | 9.40 | 9.00 | 8.30 | 8.40 | 9.90 | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 |
Sun Pharmaceutical
1,839.90
+10.50
(0.57%)
Market Cap
4,41,453.64 Cr
EPS
39.90
PE Ratio
37.20
Dividend Yield
0.74 %
Industry
Healthcare52 Week High
1,960.35
52 Week Low
1,377.20
PB Ratio
6.35
Debt to Equity
0.08
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from31 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,839.90 | #1 4,41,453.64 | #6 37.20 | #1 49,887.20 | #7 12.06 | #1 9,648 | #6 13.77 | 61.42 | |
6,136.50 | 1,62,904.79 | 78.35 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 60.23 | |
1,538.00 | 1,24,211.18 | 24.70 | 26,520.70 | 14.17 | 4,155 | 47.38 | 54.81 | |
3,272.20 | 1,10,746.12 | 59.18 | 10,785.70 | 11.59 | 1,656 | 13.54 | 51.65 | |
2,403.10 | 99,146.75 | 48.14 | 10,615.60 | 19.57 | 1,942 | -16.38 | 43.55 | |
1,168.70 | 97,522.80 | #1 18.38 | 28,905.40 | 12.36 | 5,578 | 1.69 | 54.72 | |
2,088.40 | 95,344.01 | 32.75 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 52.09 | |
891.95 | 89,751.04 | 19.65 | 19,831.50 | 13.82 | 3,831 | 29.92 | 52.20 | |
1,244.00 | 72,251.72 | 19.97 | 29,559.20 | 17.55 | 3,169 | -10.04 | 55.30 | |
30,635.00 | 65,097.24 | 48.97 | 6,097.20 | 10.80 | 1,201 | 16.01 | 55.94 |
Growth Rate
Revenue Growth
12.06 %
Net Income Growth
12.70 %
Cash Flow Change
144.69 %
ROE
-0.35 %
ROCE
5.02 %
EBITDA Margin (Avg.)
4.46 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,463 |
| Fixed Assets | 12,683 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,211 |
| Current Assets | 29,122 | 29,941 | 32,954 | 31,636 | 31,069 | 31,654 | 30,442 | 34,865 | 39,862 | 43,433 |
| Capital Work in Progress | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 |
| Investments | 2,117 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 |
| Other Assets | 32,189 | 35,653 | 39,742 | 36,056 | 33,544 | 34,042 | 34,935 | 33,007 | 36,881 | 41,872 |
| Total Liabilities | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,463 |
| Current Liabilities | 16,353 | 13,144 | 17,887 | 19,864 | 17,340 | 15,706 | 16,146 | 17,208 | 19,906 | 16,984 |
| Non Current Liabilities | 4,186 | 5,319 | 3,093 | 2,454 | 2,632 | 3,421 | 2,041 | 1,533 | 1,522 | 1,373 |
| Total Equity | 28,489 | 37,068 | 40,431 | 42,198 | 44,723 | 49,125 | 49,480 | 51,066 | 59,316 | 67,106 |
| Reserve & Surplus | 25,383 | 32,741 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 |
| Share Capital | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 2,927 | 848 | 611 | -736 | -844 | -1,386 | 596 | -1,765 | 116 | 4,662 |
| Investing Activities | -1,502 | -3,949 | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,220 | -763 |
| Operating Activities | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 |
| Financing Activities | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,981 | -5,194 | 2,376 | -6,710 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.79 % | 0.00 % | 17.72 % | 17.23 % | 18.02 % | 18.05 % | 17.96 % |
| DIIs | 21.59 % | 21.93 % | 21.67 % | 20.94 % | 19.94 % | 19.57 % | 18.60 % | 19.14 % | 19.24 % | 19.75 % | 19.67 % | 17.97 % | 18.83 % | 19.28 % | 18.61 % | 18.55 % | 18.70 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.34 % | 7.21 % | 6.79 % | 6.68 % | 6.49 % | 6.31 % | 5.91 % | 5.76 % | 5.70 % | 5.65 % | 5.56 % | 5.41 % | 5.44 % | 5.57 % | 5.43 % | 5.47 % | 5.42 % |
| Others | 16.60 % | 16.38 % | 17.05 % | 17.90 % | 19.09 % | 19.64 % | 21.01 % | 20.63 % | 20.58 % | 20.12 % | 3.51 % | 22.13 % | 3.53 % | 3.44 % | 3.46 % | 3.46 % | 3.45 % |
| No of Share Holders | 0 | 7,09,045 | 7,57,366 | 6,75,908 | 6,80,800 | 6,62,384 | 6,47,167 | 6,43,512 | 6,25,252 | 6,24,561 | 6,16,588 | 6,12,626 | 6,31,392 | 6,73,217 | 6,57,317 | 6,89,623 | 7,04,983 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.5 | 2 | 2.75 | 4 | 7.5 | 10 | 11.5 | 13.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.71 | 0.42 | 0.78 | 0.67 | 0.82 | 1.01 | 0.71 | 0.78 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 Feb 2025 |  Dividend | ₹ 10.50 /share | 06 Feb 2025 | 1,739.10 | 1,753.40 |
| 31 Jan 2025 |  Quarterly Result Announcement | NA | 31 Jan 2025 | 1,756.85 | 1,739.10 |
| 21 Jan 2025 |  Extraordinary General Meeting | NA | 21 Jan 2025 | 1,806.20 | 1,778.25 |
| 28 Oct 2024 | Quarterly Result Announcement | NA | 28 Oct 2024 | 1,916.85 | 1,860.40 |
| 05 Aug 2024 |  Annual General Meeting | NA | 05 Aug 2024 | 1,520.65 | 1,731.65 |
| 12 Jul 2024 | Dividend | ₹ 5.00 /share | 12 Jul 2024 | 1,541.15 | 1,583.25 |
| 09 Feb 2024 | Dividend | ₹ 8.50 /share | 09 Feb 2024 | 1,371.60 | 1,500.25 |
| 28 Jul 2023 | Dividend | ₹ 4.00 /share | 28 Jul 2023 | 945.00 | 1,134.95 |
| 08 Feb 2023 | Dividend | ₹ 7.50 /share | 08 Feb 2023 | 1,050.90 | 1,005.65 |
| 22 Aug 2022 | Dividend | ₹ 3.00 /share | 19 Aug 2022 | 903.90 | 901.35 |
| 10 Feb 2022 | Dividend | ₹ 7.00 /share | 09 Feb 2022 | 827.35 | 886.45 |
| 25 Aug 2021 | Dividend | ₹ 2.00 /share | 23 Aug 2021 | 703.80 | 771.35 |
| 10 Feb 2021 | Dividend | ₹ 5.50 /share | 09 Feb 2021 | 564.35 | 623.60 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Apr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Order Vacating Preliminary Injunction On LEQSELVI™Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2025
Apr 07, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Apr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 31, 2025
Mar 31, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 26, 2025
Mar 26, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Our Investee CompanyMar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 18, 2025
Mar 18, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMar 04, 2025
Mar 04, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 04, 2025
Mar 04, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 20, 2025
Feb 20, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Feb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 17, 2025
Feb 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 06, 2025
Feb 06, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory OrderFeb 04, 2025
Feb 04, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory OrderFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Feb 04, 2025Sustainability Report For The Financial Year 2023-24Feb 03, 2025
Feb 03, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Chief Operating OfficerFeb 03, 2025
Feb 03, 2025Q3FY25 Investor Call Audio RecordingJan 31, 2025
Jan 31, 2025Integrated Filing (Financial)Jan 31, 2025
Jan 31, 2025Corporate Action-Board approves DividendJan 31, 2025
Jan 31, 2025Outcome Of The Board Meeting Held Today I.E. January 31 2025Jan 31, 2025
Jan 31, 2025Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingJan 21, 2025
Jan 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 17, 2025
Jan 17, 2025Intimation Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revision In Record DateJan 16, 2025
Jan 16, 2025Corporate Action-Board to consider DividendJan 16, 2025
Jan 16, 2025Board Meeting Intimation for Approval Of Financial Results For Quarter And Nine Months Ended December 31 2024 And Interim DividendJan 16, 2025
Jan 16, 2025Announcement under Regulation 30 (LODR)-AcquisitionJan 16, 2025
Jan 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Jan 13, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Sale Of SubsidiaryDec 31, 2024
Dec 31, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 17, 2024
Dec 17, 2024Notice Of The National Company Law Tribunal Convened Meeting Of Equity Shareholders On January 21, 2025Dec 16, 2024
Dec 16, 2024Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory OrderDec 13, 2024
Dec 13, 2024Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory OrderDec 12, 2024
Dec 12, 2024Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Update On Regulatory OrderDec 11, 2024
Dec 11, 2024National Company Law Tribunal Convened Meeting Of Equity Shareholders Shall Be Held On Tuesday, January 21, 2025 At 3:00 P.M. IST By Video Conferencing.Dec 10, 2024
Dec 10, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 10, 2024
Dec 10, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 06, 2024
Dec 06, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 28, 2024
Nov 28, 2024Announcement under Regulation 30 (LODR)-Investor PresentationNov 28, 2024
Nov 28, 2024Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory OrderNov 28, 2024
Nov 28, 2024Technical Indicators
RSI(14)
Neutral 61.42
ATR(14)
Less Volatile 47.37
STOCH(9,6)
Overbought 87.06
STOCH RSI(14)
Overbought 80.64
MACD(12,26)
Bullish 10.40
ADX(14)
Weak Trend 23.63
UO(9)
Bearish 62.92
ROC(12)
Uptrend And Accelerating 8.41
WillR(14)
Overbought -10.32
About Sun Pharmaceutical
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
